Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Novartis Subsidiary Launches Offer to Acquire All Outstanding Shares of Regulus Therapeutics for $7.00 in Cash Plus Additional $7.00 Contingent Value Right Per Share, with Offer Expiring at 12:01 A.M. ET on June 25, 2025, Unless Extended or Terminated

Author: Benzinga Newsdesk | May 27, 2025 08:16am

Posted In: NVS RGLS